CIK 0001728117 · Non-accelerated filer<br>Smaller reporting company
Gossamer Bio, Inc.
Sign in to watch- Ticker
- GOSS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 475461709
- Phone
- (858) 684-1300
- Business address
- 3115 MERRYFIELD ROW, SUITE 120, SAN DIEGO, CA, 92121
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-19 | Hasnain Faheem President & CEO | Returned to the company · Stock Option (Right to Buy) | −650,000 | 0 | ||
| 2026-03-19 | Hasnain Faheem President & CEO | Returned to the company · Stock Option (Right to Buy) | −325,000 | 0 | ||
| 2026-03-19 | Hasnain Faheem President & CEO | Returned to the company · Stock Option (Right to Buy) | −47,000 | 0 | ||
| 2026-03-19 | Hasnain Faheem President & CEO | Returned to the company · Stock Option (Right to Buy) | −43,500 | 0 | ||
| 2026-03-19 | Hasnain Faheem President & CEO | Grant or award · Stock Option (Right to Buy) | +1,680,000 | 1,680,000 | ||
| 2026-03-19 | Hasnain Faheem President & CEO | Grant or award · Stock Option (Right to Buy) | +1,540,000 | 1,540,000 | ||
| 2026-03-19 | Hasnain Faheem President & CEO | Grant or award · Stock Option (Right to Buy) | +1,312,500 | 1,312,500 | ||
| 2026-03-19 | Hasnain Faheem President & CEO | Grant or award · Stock Option (Right to Buy) | +437,500 | 437,500 | ||
| 2026-03-19 | Hasnain Faheem President & CEO | Grant or award · Stock Option (Right to Buy) | +544,500 | 544,500 | ||
| 2026-03-19 | Hasnain Faheem President & CEO | Grant or award · Stock Option (Right to Buy) | +544,500 | 544,500 | ||
| 2026-03-19 | Hasnain Faheem President & CEO | Grant or award · Stock Option (Right to Buy) | +650,000 | 650,000 | ||
| 2026-03-19 | Hasnain Faheem President & CEO | Grant or award · Stock Option (Right to Buy) | +325,000 | 325,000 | ||
| 2026-03-19 | Hasnain Faheem President & CEO | Grant or award · Stock Option (Right to Buy) | +47,000 | 47,000 | ||
| 2026-03-19 | Hasnain Faheem President & CEO | Grant or award · Stock Option (Right to Buy) | +43,500 | 43,500 | ||
| 2026-01-02 | Smith Robert Paul JR Chief Commercial Officer | Grant or award | +93,750 | 260,898 | ||
| 2026-01-02 | Smith Robert Paul JR Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +562,500 | 562,500 | ||
| 2026-01-02 | Aranda Richard Chief Medical Officer | Grant or award | +93,750 | 463,106 | ||
| 2026-01-02 | Aranda Richard Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +562,500 | 562,500 | ||
| 2026-01-02 | Peterson Caryn EVP, Regulatory Affairs | Grant or award | +84,500 | 259,333 | ||
| 2026-01-02 | Peterson Caryn EVP, Regulatory Affairs | Grant or award · Stock Option (Right to Buy) | +506,250 | 506,250 |
Page 7 of 14 · 262 trades